Campath: Benefit /Risk
CAM211: advanced refractory population
- Majority had received salvage therapy after failing fludarabine
- Immunocompromised at study entry
- Compromised marrow at study entry
- No approved or effective therapies
Effective and manageably safe
Addresses significant unmet need